Transdermal drug delivery: feasibility for treatment of superficial bone stress fractures

详细信息    查看全文

• 作者：Ali Aghazadeh-Habashi ; Yang Yang ; Kathy Tang…
• 关键词：Stress fractures ; Transdermal drug delivery ; Transdermal drug delivery systems (TDDS) ; Superficial bone ; Peptide hormones ; Bone pain ; Analgesia
• 刊名：Drug Delivery and Translational Research
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：5
• 期：6
• 页码：540-551
• 全文大小：671 KB
• 参考文献：1.Haegerstam GAT. Pathophysiology of bone pain: a review. Acta Orthop Scand. 2001;72(3):308鈥?7.PubMed
  2.Patel DS, Roth M, Kapil N. Stress fractures: diagnosis, treatment, and prevention. Am Fam Physician. 2011;83(1):39鈥?6.PubMed
  3.Carmont MR, Mei-Dan O, Bennell KL. Stress fracture management: current classification and new healing modalities. Oper Tech Sports Med. 2009;17(2):81鈥?.
  4.Jacobs JM, Cameron KL, Bojescul JA. Lower extremity stress fractures in the military. Clin Sports Med. 2014;33(4):591鈥?13.PubMed
  5.Aweid B, Aweid O, Talibi S, Porter K. Stress fractures. Trauma (UK). 2013;15(4):308鈥?1.
  6.McCormick F, Nwachukwu BU, Provencher MT. Stress fractures in runners. Clin Sports Med. 2012;31(2):291鈥?06.PubMed
  7.Moen MH, Tol JL, Weir A, Steunebrink M, Winter TCD. Medial tibial stress syndrome: a critical review. Sports Med. 2009;39(7):523鈥?6.PubMed
  8.Houghton AK, Hewitt E, Westlund KN. Enhanced withdrawal responses to mechanical and thermal stimuli after bone injury. Pain. 1997;73(3):325鈥?7.PubMed
  9.Kawaguchi H, Pilbeam CC, Harrison JR, Raisz LG. The role of prostaglandins in the regulation of bone metabolism. Clin Orthop Relat Res. 1995;313:36鈥?6.PubMed
  10.Wheeler P, Batt ME. Do non-steroidal anti-inflammatory drugs adversely affect stress fracture healing? A short review. Br J Sports Med. 2005;39(2):65鈥?.PubMedCentral PubMed
  11.Ziltener JL, Leal S, Fournier PE. Non-steroidal anti-inflammatory drugs for athletes: an update. Ann Phys Rehabil Med. 2010;53(4):278鈥?8.PubMed
  12.Brandt KD. Osteophytes in osteoarthritis. Clin Aspects Osteoarthr Cartil. 1999;7(3):334鈥?.
  13.Kaeding CC, Najarian RG. Stress fractures: classification and management. Phys Sportsmedicine. 2010;38(3):45鈥?4.PubMed
  14.Koga T, Niikura T, Lee SY, Okumachi E, Ueha T, Iwakura T, et al. Topical cutaneous CO application by means of a novel hydrogel accelerates fracture repair in rats. J Bone Joint Surg-Am Vol. 2014;96(24):2077鈥?4.
  15.Carr K, Sevetson E, Aukerman D. How can you help athletes prevent and treat shin splints? J Fam Pract. 2008;57(6):406鈥?.PubMed
  16.Biber Brewer R, Gregory AJM. Chronic lower leg pain in athletes: a guide for the differential diagnosis, evaluation, and treatment. Sports Health. 2012;4(2):121鈥?.
  17.Mason L, Moore RA, Derry S, Edwards JE, McQuay HJ. Systematic review of topical capsaicin for the treatment of chronic pain. Br Med J. 2004;328(7446):991鈥?.
  18.Gomberg SJ, Wustrack RL, Napoli N, Arnaud CD, Black DM. Teriparatide, vitamin D, and calcium healed bilateral subtrochanteric stress fractures in a postmenopausal woman with a 13-year history of continuous alendronate therapy. J Clin Endocrinol Metab. 2011;96(6):1627鈥?2.PubMed
  19.Fr枚lich M, Giannotti A, Modell JH. Opioid overdose in a patient using a fentanyl patch during treatment with a warming blanket. Anesth Analg. 2001;93(3):647鈥?.PubMed
  20.Leung FW. Capsaicin as an anti-obesity drug. Prog Drug Res. 2014. 171鈥?.
  21.Haanp盲盲 M, Treede RD. Capsaicin for neuropathic pain: linking traditional medicine and molecular biology. Eur Neurol. 2012;68(5):264鈥?5.PubMed
  22.O鈥橬eill J, Brock C, Olesen AE, Andresen T, Nilsson M, Dickenson AH. Unravelling the mystery of capsaicin: a tool to understand and treat pain. Pharmacol Rev. 2012;64(4):939鈥?1.PubMedCentral PubMed
  23.Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8 patch. Br J Anaesth. 2011;107(4):490鈥?02.PubMedCentral PubMed
  24.Glass GG. Osteoarthritis. Dis-A-Month. 2006;52(9):343鈥?2.
  25.Sharma SK, Vij AS, Sharma M. Mechanisms and clinical uses of capsaicin. Eur J Pharmacol. 2013;720(1鈥?):55鈥?2.PubMed
  26.Zhang Q, Tan TT, Peng Y. Influence of capsaicin on visceral hyperalgesia and its mechanism. World Chin Jof Digestol. 2008;16(34):3884鈥?.
  27.McCleane G. Topical analgesics. Perioper Nurs Clin. 2009;4(4):391鈥?03.
  28.Argoff CE. Topical treatments for pain. Curr Pain Headache Rep. 2004;8(4):261鈥?.PubMed
  29.Jorge LL, Feres CC, Teles VEP. Topical preparations for pain relief: efficacy and patient adherence. J Pain Res. 2011;4:11鈥?4.PubMedCentral
  30.Stanos SP. Topical agents for the management of musculoskeletal pain. J Pain Symptom Manag. 2007;33(3):342鈥?5.
  31.Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261鈥?.PubMedCentral PubMed
  32.MacKie RM. Clinical dermatology. 5th ed. Oxford: Oxford University Press; 2003.
  33.Schmook FP, Meingassner JG, Billich A. Comparison of human skin or epidermis models with human and animal skin in in-vitro percutaneous absorption. Int J Pharm. 2001;215(1鈥?):51鈥?.PubMed
  34.Barbero AM, Frasch HF. Pig and guinea pig skin as surrogates for human in vitro penetration studies: a quantitative review. Toxicol in Vitro. 2009;23(1):1鈥?3.PubMed
  35.Godin B, Touitou E. Transdermal skin delivery: predictions for humans from in vivo, ex vivo and animal models. Adv Drug Deliv Rev. 2007;59(11):1152鈥?1.PubMed
  36.Netzlaff F, Schaefer UF, Lehr CM, Meiers P, Stahl J, Kietzmann M, et al. Comparison of bovine udder skin with human and porcine skin in percutaneous permeation experiments. ATLA Altern Lab Anim. 2006;34(5):499鈥?13.PubMed
  37.Bouwstra JA, Ponec M. The skin barrier in healthy and diseased state. Biochim Biophys Acta Biomembr. 2006;1758(12):2080鈥?5.
  38.Norl茅n L. Skin barrier structure and function: the single gel phase model. J Investig Dermatol. 2001;117(4):830鈥?.PubMed
  39.Sherwood L. Human physiology: from cells to systems. 8th ed. Belmont: Brooks/Cole, Cengage Learning; 2013.
  40.Pegoraro C, MacNeil S, Battaglia G. Transdermal drug delivery: from micro to nano. Nanoscale. 2012;4(6):1881鈥?4.PubMed
  41.El Maghraby GM, Barry BW, Williams AC. Liposomes and skin: from drug delivery to model membranes. Eur J Pharm Sci. 2008;34(4鈥?):203鈥?2.PubMed
  42.Verma A, Singh S, Kaur R, Jain UK. Topical gels as drug delivery systems: a review. Int J Pharm Sci Rev Res. 2013;23(2):374鈥?2.
  43.Schuetz YB, Naik A, Guy RH, Kalia YN. Emerging strategies for the transdermal delivery of peptide and protein drugs. Expert Opin Drug Deliv. 2005;2(3):533鈥?8.PubMed
  44.Benson HAE. Transdermal drug delivery: penetration enhancement techniques. Curr Drug Deliv. 2005;2(1):23鈥?3.PubMed
  45.Benson HAE, Watkinson AC. Transdermal and topical drug delivery: principles and practice. Transdermal Top Drug Deliv: Princ Pract. 2012.
  46.Wolff HM. Future of transdermal drug delivery systems (TDDS). Am Pharm Rev. 2014;17(4).
  47.Burnham R, Gregg R, Healy P, Steadward R. The effectiveness of topical diclofenac for lateral epicondylitis. Clin J Sport Med. 1998;8(2):78鈥?1.PubMed
  48.Grace D, Rogers J, Skeith K, Anderson K. Topical diclofenac versus placebo: a double blind, randomized clinical trial in patients with osteoarthritis of the knee. J Rheumatol. 1999;26(12):2659鈥?3.PubMed
  49.Walker RB, Smith EW. The role of percutaneous penetration enhancers. Adv Drug Deliv Rev. 1996;18(3):295鈥?01.
  50.Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev. 2004;56(5):603鈥?8.PubMed
  51.Kogan A, Garti N. Microemulsions as transdermal drug delivery vehicles. Adv Colloid Interf Sci. 2006;123-126(SPEC. ISS):369鈥?5.
  52.Sloan KB, Wasdo SC, Rautio J. Design for optimized topical delivery: prodrugs and a paradigm change. Pharm Res. 2006;23(12):2729鈥?7.PubMed
  53.Machet L, Boucaud A. Phonophoresis: efficiency, mechanisms and skin tolerance. Int J Pharm. 2002;243(1鈥?):1鈥?5.PubMed
  54.Karande P, Jain A, Mitragotri S. Discovery of transdermal penetration enhancers by high-throughput screening. Nat Biotechnol. 2004;22(2):192鈥?.PubMed
  55.Manosroi J, Lohcharoenkal W, G枚tz F, Werner RG, Manosroi W, Manosroi A. Transdermal absorption and stability enhancement of salmon calcitonin by Tat peptide. Drug Devel Ind Pharm. 2013;39(4):520鈥?.
  56.Denet AR, Pr茅at V. Transdermal delivery of timolol by electroporation through human skin. J Control Release. 2003;88(2):253鈥?2.PubMed
  57.Lombry C, Dujardin N, Pr茅at V. Transdermal delivery of macromolecules using skin electroporation. Pharm Res. 2000;17(1):32鈥?.PubMed
  58.Ogura M, Paliwal S, Mitragotri S. Low-frequency sonophoresis: current status and future prospects. Adv Drug Deliv Rev. 2008;60(10):1218鈥?3.PubMed
  59.Sivamani RK, Liepmann D, Maibach HI. Microneedles and transdermal applications. Expert opinion on drug delivery. 2007;4(1):19鈥?5.PubMed
  60.Prausnitz MR. Microneedles for transdermal drug delivery. Adv Drug Deliv Rev. 2004;56(5):581鈥?.PubMed
  61.Glenn GM, Flyer DC, Ellingsworth LR, Frech SA, Frerichs DM, Seid Jr RC, et al. Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch. Expert Rev Vaccines. 2007;6(5):809鈥?9.PubMed
  62.Colombo P, Volpato NM, Santi P. Calcitonin transdermal iontophoresis in comparison with intravenous administration. Proc Control Release Soc. 1997;24:693鈥?.
  63.Nakamura K, Katagai K, Mori K, Higo N, Sato S, Yamamoto K. Transdermal administration of salmon calcitonin by pulse depolarization鈥搃ontophoresis in rats. Int J Pharm. 2001;218(1鈥?):93鈥?02.PubMed
  64.Roustit M, Blaise S, Cracowski JL. Trials and tribulations of skin iontophoresis in therapeutics. Br J Clin Pharmacol. 2014;77(1):63鈥?1.PubMedCentral PubMed
  65.Denet AR, Vanbever R, Pr茅at V. Skin electroporation for transdermal and topical delivery. Adv Drug Deliv Rev. 2004;56(5):659鈥?4.PubMed
  66.Blagus T, Markelc B, Cemazar M, Kosjek T, Preat V, Miklavcic D, et al. In vivo real-time monitoring system of electroporation mediated control of transdermal and topical drug delivery. J Control Release. 2013;172(3):862鈥?1.PubMed
  67.Zorec B, Becker S, Reber拧ek M, Miklav膷i膷 D, Pav拧elj N. Skin electroporation for transdermal drug delivery: the influence of the order of different square wave electric pulses. Int J Pharm. 2013;457(1):214鈥?3.PubMed
  68.Sammeta SM, Vaka SRK, Murthy SN. Transcutaneous electroporation mediated delivery of doxepin鈥揌PCD complex: a sustained release approach for treatment of postherpetic neuralgia. J Control Release. 2010;142(3):361鈥?.PubMedCentral PubMed
  69.Eriksson F, T枚tterman T, Maltais AK, Pisa P, Yachnin J. DNA vaccine coding for the rhesus prostate specific antigen delivered by intradermal electroporation in patients with relapsed prostate cancer. Vaccine. 2013;31(37):3843鈥?.PubMed
  70.Livingston BD, Little SF, Luxembourg A, Ellefsen B, Hannaman D. Comparative performance of a licensed anthrax vaccine versus electroporation based delivery of a PA encoding DNA vaccine in rhesus macaques. Vaccine. 2010;28(4):1056鈥?1.PubMed
  71.Tezel A, Sens A, Tuchscherer J, Mitragotri S. Synergistic effect of low-frequency ultrasound and surfactants on skin permeability. J Pharm Sci. 2002;91(1):91鈥?00.PubMed
  72.Lopez RFV, Seto JE, Blankschtein D, Langer R. Enhancing the transdermal delivery of rigid nanoparticles using the simultaneous application of ultrasound and sodium lauryl sulfate. Biomaterials. 2011;32(3):933鈥?1.PubMedCentral PubMed
  73.Bawiec CR, Sunny Y, Nguyen AT, Samuels JA, Weingarten MS, Zubkov LA, et al. Finite element static displacement optimization of 20鈥?00 kHz flexural transducers for fully portable ultrasound applicator. Ultrasonics. 2013;53(2):511鈥?.PubMedCentral PubMed
  74.Moga KA, Bickford LR, Geil RD, Dunn SS, Pandya AA, Wang Y, et al. Rapidly-dissolvable microneedle patches via a highly scalable and reproducible soft lithography approach. Adv Mater. 2013;25(36):5060鈥?.PubMedCentral PubMed
  75.Kalluri H, Banga AK. Formation and closure of microchannels in skin following microporation. Pharm Res. 2011;28(1):82鈥?4.PubMed
  76.Banks SL, Paudel KS, Brogden NK, Loftin CD, Stinchcomb AL. Diclofenac enables prolonged delivery of naltrexone through microneedle-treated skin. Pharm Res. 2011;28(5):1211鈥?.PubMedCentral PubMed
  77.Park JH, Lee JW, Kim YC, Prausnitz MR. The effect of heat on skin permeability. Int J Pharm. 2008;359(1鈥?):94鈥?03.PubMedCentral PubMed
  78.Lee JW, Gadiraju P, Park JH, Allen MG, Prausnitz MR. Microsecond thermal ablation of skin for transdermal drug delivery. J Control Release. 2011;154(1):58鈥?8.PubMedCentral PubMed
  79.Fujimoto T, Shirakami K, Tojo K. Effect of microdermabrasion on barrier capacity of stratum corneum. Chem Pharm Bull. 2005;53(8):1014鈥?.PubMed
  80.Gill HS, Andrews SN, Sakthivel SK, Fedanov A, Williams IR, Garber DA, et al. Selective removal of stratum corneum by microdermabrasion to increase skin permeability. Eur J Pharm Sci. 2009;38(2):95鈥?03.PubMedCentral PubMed
  81.Allen LV. Amitriptyline 10%, Baclofen 2.5%, and Ketamine 5% in PLO Gel. US Pharm. 2015;40(3):48鈥?.
  82.Cevc G. Transfersomes, liposomes and other lipid suspensions on the skin: permeation enhancement, vesicle penetration, and transdermal drug delivery. Crit Rev Ther Drug Carrier Syst. 1996;13(3鈥?):257鈥?88.PubMed
  83.Benson HAE, Namjoshi S. Proteins and peptides: strategies for delivery to and across the skin. J Pharm Sci. 2008;97(9):3591鈥?10.PubMed
  84.Gupta PN, Singh P, Mishra V, Jain S, Dubey PK, Vyas SP. Topical immunization: mechanistic insight and novel delivery systems. Indian J Biotechnol. 2004;3(1):9鈥?1.
  85.Gupta PN, Vyas SP, Vishwidyalaya HSG. Transfersomes for vaccine delivery: a potential approach for topical immunization. Med Chem Res. 2004;13(6鈥?):414鈥?6.
  86.Zhang L, Li L, An Z, Hoffman RM, Hofmann GA. In vivo transdermal delivery of large molecules by pressure-mediated electroincorporation and electroporation: a novel method for drug and gene delivery. Bioelectrochem Bioenerg. 1997;42(2):283鈥?2.
  87.Prausnitz MR. Transdermal delivery of macromolecules: recent advances by modification of skin鈥檚 barrier properties. ACS Symp Ser. 1997. 124鈥?3.
  88.Benson HAE. Transfersomes for transdermal drug delivery. Expert Opin Drug Deliv. 2006;3(6):727鈥?7.PubMed
  89.Li H, Yu Y, Faraji Dana S, Li B, Lee CY, Kang L. Novel engineered systems for oral, mucosal and transdermal drug delivery. J Drug Target. 2013;21(7):611鈥?9.PubMed
  90.Brown MB, Traynor MJ, Martin GP, Akomeah FK. Transdermal drug delivery systems: skin perturbation devices. Methods Mol Biol. 2008. 119鈥?9.
  91.Gratieri T, Kalaria D, Kalia YN. Non-invasive iontophoretic delivery of peptides and proteins across the skin. Expert Opin Drug Deliv. 2011;8(5):645鈥?3.PubMed
  92.Godin B, Touitou E. Ethosomes: new prospects in transdermal delivery. Crit Rev Ther Drug Carrier Syst. 2003;20(1):63鈥?02.PubMed
  93.Sadrzadeh N, Glembourtt MJ, Stevenson CL. Peptide drug delivery strategies for the treatment of diabetes. J Pharm Sci. 2007;96(8):1925鈥?4.PubMed
  94.Cevc G. Transdermal drug delivery of insulin with ultradeformable carriers. Clin Pharmacokinet. 2003;42(5):461鈥?4.PubMed
  95.Jain A, Gulbake A, Shilpi S, Hurkat P, Jain SK. Peptide and protein delivery using new drug delivery systems. Crit Rev Ther Drug Carrier Syst. 2013;30(4):293鈥?29.PubMed
  96.Pun KK, Chan LWL. Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin Ther. 1989;11(2):205鈥?.PubMed
  97.Lyritis GP, Paspati L, Karachalios T, Ioakimidis D, Skarantavos G, Lyritis PG. Pain relief from nasal salmon calcitonin in osteoporotic vertebral crush fractures. A double blind, placebo-controlled clinical study. Acta Orthop Scand Suppl. 1997;68(275):112鈥?.
  98.Lyritis GP, Trovas G. Analgesic effects of calcitonin. Bone. 2002;30(5 SUPPL 1):71S鈥?.PubMed
  99.Combe B, Cohen C, Aubin F. Equivalence of nasal spray and subcutaneous formulations of salmon calcitonin. Calcif Tissue Int. 1997;61(1):10鈥?.PubMed
  100.Blau LA, Hoehns JD, Nazario M, Gagnon L. Analgesic efficacy of calcitonin for vertebral fracture pain. Ann Pharmacother. 2003;37(4):564鈥?0.PubMed
  101.Silverman SL, Azria M. The analgesic role of calcitonin following osteoporotic fracture. Osteoporos Int. 2002;13(11):858鈥?7.PubMed
  102.Peichl P, Rintelen B, Kumpan W, Br枚ll H. Increase of axial and appendicular trabecular and cortical bone density in established osteoporosis with intermittent nasal salmon calcitonin therapy. Gynecol Endocrinol. 1999;13(1):7鈥?4.PubMed
  103.Abellan Perez M, Bayina Garcia FJ, Calabozo M, Carpintero Benitez P, Figueroa Pedrosa M, Fernandez Crisostomo MC, et al. Multicentric comparative study of synthetic salmon calcitonin nasally administered in the treatment of established postmenopausic osteoporosis. An Med Interna. 1995;12(1):12鈥?.PubMed
  104.Ringe JD, Welzel D. Salmon calcitonin in the therapy of corticoid-induced osteoporosis. Eur J Clin Pharmacol. 1987;33(1):35鈥?.PubMed
  105.Knopp-Sihota JA, Newburn-Cook CV, Homik J, Cummings GG, Voaklander D. Calcitonin for treating acute and chronic pain of recent and remote osteoporotic vertebral compression fractures: a systematic review and meta-analysis. Osteoporos Int. 2012;23(1):17鈥?8.PubMed
  106.Kirk JK, Hepfinger C. Calcitonin. Clin Rev Bone Mineral Metab. 2005;3(1):39鈥?9.
  107.Huusko TM, Karppi P, Kautiainen H, Suominen H, Avikainen V, Sulkava R. Randomized, double-blind, clinically controlled trial of intranasal calcitonin treatment in patients with hip fracture. Calcif Tissue Int. 2002;71(6):478鈥?4.PubMed
  108.Brown JP, Josse RG. 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. CMAJ. 2002;167(10):S1鈥?4.PubMedCentral PubMed
  109.Chau A. The role of calcitonin for fracture pain. Can Pharm J. 2006;139(1):46鈥?0.
  110.Badurski J, Jeziernicka E, Naruszewicz K, Racewicz A. Comparative analysis of three treatment regimens for treating gonarthritis with calcitonin, naproxen and flavonoids based on EULAR criteria and visual analogue scale (VAS). Pol Tyg Lek (Warsaw, Poland: 1960). 1995;50(44鈥?7):37鈥?0.
  111.Tsavaris N, Kopterides P, Kosmas C, Vadiaka M, Dimitrakopoulos A, Scopelitis H, et al. Analgesic activity of high-dose intravenous calcitonin in cancer patients with bone metastases. Oncol Rep. 2006;16(4):871鈥?.PubMed
  112.Goicoechea C, Ormaz谩bal MJ, Alfaro MJ, Mart铆n MI. Effect of salmon-calcitonin on the analgesic effect of selective 渭, 未 and 魏 opioid agonists in mice. Neurosci Lett. 1999. 25鈥?.
  113.Chang SL, Hofmann GA, Zhang L, Deftos LJ, Banga AK. Transdermal iontophoretic delivery of salmon calcitonin. Int J Pharm. 2000;200(1):107鈥?3.PubMed
  114.Tas C, Mansoor S, Kalluri H, Zarnitsyn VG, Choi SO, Banga AK, et al. Delivery of salmon calcitonin using a microneedle patch. Int J Pharm. 2012;423(2):257鈥?3.PubMedCentral PubMed
  115.Manosroi A, Chankhampan C, Manosroi W, Manosroi J. Enhancement of chemical stability and transdermal absorption of salmon calcitonin loaded in elastic niosomes. Adv Sci Lett. 2012;5(1):314鈥?.
  116.Bhandari KH, Asghar W, Newa M, Jamali F, Doschak MR. Evaluation of bone targeting salmon calcitonin analogues in rats developing osteoporosis and adjuvant arthritis. Curr Drug Deliv. 2015;12(1):98鈥?07.PubMed
  117.Segvich S, Biswas S, Becker U, Kohn DH. Identification of peptides with targeted adhesion to bone-like mineral via phage display and computational modeling. Cells Tissues Organs. 2008;189(1鈥?):245鈥?1.PubMedCentral PubMed
  118.Addison WN, Miller SJ, Ramaswamy J, Mansouri A, Kohn DH, McKee MD. Phosphorylation-dependent mineral-type specificity for apatite-binding peptide sequences. Biomaterials. 2010;31(36):9422鈥?0.PubMedCentral PubMed
  119.Dobnig H, Turner RT. The effects of programmed administration of human parathyroid hormone fragment (1鈥?4) on bone histomorphometry and serum chemistry in rats. Endocrinology. 1997;138(11):4607鈥?2.PubMed
  120.Brixen KT, Christensen PM, Ejersted C, Langdahl BL. Teriparatide (biosynthetic human parathyroid hormone 1鈥?4): a new paradigm in the treatment of osteoporosis. Basic Clin Pharmacol Toxicol. 2004;94(6):260鈥?0.PubMed
  121.Suzuki Y, Iga K, Yanai S, Matsumoto Y, Kawase M, Fukuda T, et al. Iontophoretic pulsatile transdermal delivery of human parathyroid hormone (1鈥?4). J Pharm Pharmacol. 2001;53(9):1227鈥?4.PubMed
  122.Suzuki Y, Nagase Y, Katsumi IGA, Kawase M, Masahiro OKA, Yanai S, et al. Prevention of bone loss in ovariectomized rats by pulsatile transdermal iontophoretic administration of human PTH(1鈥?4). J Pharm Sci. 2002;91(2):350鈥?1.PubMed
  123.Medi BM, Singh J. Electronically facilitated transdermal delivery of human parathyroid hormone (1鈥?4). Int J Pharm. 2003;263(1鈥?):25鈥?3.PubMed
  124.Chang SL, Hofmann GA, Zhang L, Deftos LJ, Banga AK. The effect of electroporation on iontophoretic transdermal delivery of calcium regulating hormones. J Control Release. 2000;66(2鈥?):127鈥?3.PubMed
  125.Morley P. Delivery of parathyroid hormone for the treatment of osteoporosis. Expert Opin Drug Deliv. 2005;2(6):993鈥?002.PubMed
  126.Gopalakrishnan V, Hwang S, Loughrey H, Alexandre B, Desai D, Haiying L, et al. Administration of ThPTH to humans using Macroflux庐 transdermal technology results in the rapid delivery of biologically active PTH. J Bone Miner Res. 2004;19(supplement S1):S460鈥揗84.
  127.Daddona PE, Matriano JA, Mandema J, Maa YF. Parathyroid hormone (1鈥?4)-coated microneedle patch system: clinical pharmacokinetics and pharmacodynamics for treatment of osteoporosis. Pharm Res. 2011;28(1):159鈥?5.PubMed
  
• 作者单位：Ali Aghazadeh-Habashi (1)
  Yang Yang (1)
  Kathy Tang (1)
  Raimar L艖benberg (1)
  Michael R. Doschak (1)
  
  1. Faculty of Pharmacy and Pharmaceutical Sciences, 2-020J Katz Group Centre for Pharmacy and Health Research, University of Alberta, 11361-87 Ave., Edmonton, Alberta, T6G 2E1, Canada
  
• 刊物主题：Pharmaceutical Sciences/Technology;
• 出版者：Springer US
• ISSN：2190-3948

文摘

Transdermal drug delivery offers the promise of effective drug therapy at selective sites of pathology whilst reducing systemic exposure to the pharmaceutical agents in off-target organs and tissues. However, that strategy is often limited to cells comprising superficial tissues of the body (rarely to deeper bony structures) and mostly indicated with small hydrophobic pharmacological agents, such as steroid hormones and anti-inflammatory gels to skin, muscle, and joints. Nonetheless, advances in transdermal liposomal formulation have rendered the ability to readily incorporate pharmacologically active hydrophilic drug molecules and small peptide biologics into transdermal dosage forms to impart the effective delivery of those bioactive agents across the skin barrier to underlying superficial tissue structures including bone, often enhanced by some form of electrical, chemical, and mechanical facilitation. In the following review, we evaluate transdermal drug delivery systems, with a particular focus on delivering therapeutic agents to treat superficial bone pain, notably stress fractures. We further introduce and discuss several small peptide hormones active in bone (such as calcitonins and parathyroid hormone) that have shown potential for transdermal delivery, often under the added augmentation of transdermal drug delivery systems that employ lipo/hydrophilicity, electric charge, and/or microprojection facilitation across the skin barrier. Keywords Stress fractures Transdermal drug delivery Transdermal drug delivery systems (TDDS) Superficial bone Peptide hormones Bone pain Analgesia